Intracellular T3 deficiency Intracellular T3 deficiency, referred to in this article as Intracellular Hypothyroidism (IH), has been given many names, but has not been recognized as a bona fide metabolic abnormality deserving of a formal title.Thus although the condition was definitively described in 2014, it has been ignored by mainstream medicine and its diagnostic panel has yet to be added to the medical armamentarium.It is time to accept this ubiquitous metabolic abnormality as the pervasive, important syndrome which it is.This article therefore is intended to educate the public, and not least, my colleagues, on the subject of intracellular thyroid 3…
-
-
PFS is due to 5-alpha reductase blockade, producing Allopregnanolone deficiency.
-
CFS is a type of intracellular hypothyroidism. A thyroid profile (TSH, T4, FT3, rT3)is diagnostic. Slow-release triiodothyronine is curative.
-
PFS is due to 5-alpha reductase blockade, leading to Allopregnanolone deficiency and Functional Hypothyroidism. It should be treatable.
-
Jacqueline Jonklaas, Professor in the endocrinology division at Georgetown University, has submitted a paper entitled “Evidence-Based Use of Levothyroxine/Liothyronine Combinations in TreatingHypothyroidism” Below are excerpts from a (2nd March, 2021) report in Medscape Medical News: “Numerous trials have been conducted on short-acting liothyronine (LT3) in combination with the standard therapy of levothyroxine (LT4). However, the experts agreed that shortcomings in the existing studies and mounting unanswered questions need to be addressed, Jacqueline Jonklaas, MD, PhD, told Medscape Medical News“…………… “Patient-reported outcomes were acknowledged as essential in the full picture of understanding treatment efficacy, and the experts agreed that an emphasis on those outcomes will be…
You must be logged in to post a comment.